Conference Correspondent

Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma. Read More ›

Nivolumab plus ipilimumab demonstrated improvement in overall survival for patients with metastatic uveal melanoma. Read More ›

Evidence suggests fedratinib, a selective JAK2 inhibitor, demonstrates safety and efficacy in patients with myelofibrosis previously treated with ruxolitinib with appropriate mitigation strategies. Read More ›

Patients with advanced myelofibrosis and heavy mutation burden have limited safe and effective therapeutic options. Preliminary clinical trial evidence indicates bomedemstat provides clinical benefit to patients in this population. Read More ›

Patients with a low platelet count represent a difficult-to-treat group because ruxolitinib treatment is typically first-line therapy for myelofibrosis and is associated with suboptimal or loss of response and thrombocytopenia. Parsaclisib may be an effective add-on option for this patient subgroup. Read More ›

FREEDOM2 is the first trial to compare fedratinib to best available therapies, including ruxolitinib and other JAK inhibitors, in patients with myelofibrosis who were previously treated with ruxolitinib for at least 3 months. Read More ›

The rate of thrombus formation in patients with myelofibrosis is not well-defined. The intersection of IPSS score and JAK mutation may reliably indicate risk of vascular events in these patients. Read More ›

Myelofibrosis is associated with poor overall survival and clinical outcomes. Treatment with ruxolitinib earlier in disease course shows promise for improving symptoms and overall survival. Read More ›

First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma. Read More ›